Early-Phase Trial of Vaccine in NSCLC

이미지를 클릭하면 해당 사이트로 이동합니다.

---

Novel Vaccine for Lung Cancer Moves Into Phase I Clinical Trial

By: Kayci Reyer 
Posted: Wednesday, August 1, 2018

An innovative vaccine for patients with non–small cell lung cancer (NSCLC) is being developed in the UK. The stem cell–based immunotherapy treatment, known as AST-VAC2, is moving into a phase I clinical trial.
“Vaccines that boost the immune system to recognize and fight cancer could become a routine part of treatment for certain patients in the future,” shared Professor Christian Ottensmeier, MD, PhD, of Southampton Experimental Cancer Medicines Centre and lead investigator for the phase I trial, in a press release from Cancer Research UK.
The treatment uses dendritic cells (derived from a standardized line of human embryonic cells) that have been designed to produce a modified version of telomerase, an antigen usually found in high numbers in cancer cells. The presence of these dendritic cells will stimulate an immune system response against the antigen, thereby targeting the cancer cells. If AST-VAC2 proves to be safe and effective, researchers believe it may become a treatment option for patients with cancers other than NSCLC.
Previous therapies containing dendritic cells have used a patient’s own stem cells, but the slow development and high cost of those treatments have reduced their efficacy. By developing dendritic cells from a single stem cell source, Professor Ottensmeier and colleagues hope to improve the outcomes associated with cancer vaccines.

비소세포 폐암(NSCLC) 환자를 위한 혁신적인 백신이 영국에서 개발 중입니다. AST-VAC2로 알려진 stem cell–based immunotherapy 치료는 phase I clinical trial로 옮겨 가고 있습니다. 

Cancer Research UK 보도 자료에서 "암을 인식하고 싸우는 면역 체계를 향상시키는 백신은 미래에 특정 환자에서 일상적인 치료의 일부가 될 수있다"라고  Southampton Experimental Cancer Medicines Center의 교수이고 phase I trial을 이끌고 있는 Christian Ottensmeier, MD, PhD가 말했습니다.

이 치료법은 암세포에서 아주 많이 발견되는 항원인 modified version of telomerase을 생산하도록 고안된 dendritic cell(derived from a standardized line of human embryonic cells)을 사용합니다. 이러한 dendritic cell의 존재는 immune system response을 자극하여 암세포를 표적으로 합니다. 만일 AST-VAC2가 안전하고 효과적이라고 판명되면 NSCLC 이외의 암 환자에서치료 옵션이 될 수 있다고 연구원은 믿습니다. 

Dendritic cell를 포함한 이전 치료법은 환자 자신의 줄기 세포를 사용했지만, 개발이 늦고 비용이 많이 들어 효율이 감소했습니다. 단일 줄기 세포 공급원에서 dendritic cells을 개발함으로써 Ottensmeier 교수와 동료들은 암 백신과 관련된 결과를 개선하기를 희망합니다.